This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
The purpose of this study is to test the effectiveness of semaglutide 2.4 mg SQ weekly in patients with obesity with a positive MyPhenome test for abnormal postprandial satiety compared to patients with obesity with a negative MyPhenome test for abnormal postprandial satiety.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
135
2.4 mg subcutaneous weekly
Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly
Mayo Clinic in Florida
Jacksonville, Florida, United States
RECRUITINGMayo Clinic in Rochester
Rochester, Minnesota, United States
RECRUITINGChange in Total Body Weight at 24 weeks
Percent change in body weight in biomarker positive participants vs. biomarker negative participants taking semaglutide vs placebo.
Time frame: Baseline, 24 weeks
Percentage of Responders >5%
Percentage of participants who loss 5% of more of total body weight
Time frame: 24 weeks
Percentage of Responders >10%
Percentage of participants who loss 10% of more of total body weight
Time frame: 24 weeks
Percentage of Responders >15%
Percentage of participants who loss 15% of more of total body weight
Time frame: 24 weeks
Percentage of Responders >20%
Percentage of participants who loss 20% of more of total body weight
Time frame: 24 weeks
Change in Total Body Weight at 3 months
Percent change in body weight
Time frame: Baseline, 3 months
Change in Total Body Weight at 6 months
Percent change in body weight
Time frame: Baseline, 6 months
Change in Waist Circumference
Reported in centimeters (CM)
Time frame: Baseline, 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.